TuHURA Biosciences, Inc. (HURA)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q1-2026 | 8-K (2026-05-15) · 99.1 · 99.2 | 8-K (2026-04-01) · 99.1 | ||
| 10-K/A | FY-2025 | |||
| 10-KLatest | FY-2025 | — | ||
| 10-Q | Q3-2025 | 8-K (2025-11-14) · 99.1 | ||
| 10-Q | Q2-2025 | 8-K (2025-08-14) · 99.1 | ||
| 10-Q | Q1-2025 | 8-K (2025-05-15) · 99.1 | 8-K (2025-04-01) · 99.1 | 8-K (2024-10-21) · 99.1 · 99.2 · 99.3 | 8-K (2024-10-08) · 99.1 | ||
| 10-K | FY-2024 | — | ||
| 10-Q | Q1-2025 | 8-K (2025-05-15) · 99.1 | 8-K (2025-04-01) · 99.1 | 8-K (2024-10-21) · 99.1 · 99.2 · 99.3 | 8-K (2024-10-08) · 99.1 | ||
| 10-K | FY-2024 | — | ||
| 10-Q | Q3-2024 | 8-K (2024-05-14) · 99.1 | ||
| 10-Q | Q2-2024 | 8-K (2024-02-14) · 99.1 | ||
| 10-Q | Q3-2023 | 8-K (2023-05-11) · 99.1 | ||
| 10-Q | Q2-2023 | 8-K (2023-02-14) · 99.1 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Document and Entity Information | ||
| Statements | ||
| Condensed Consolidated Interim Balance Sheet | — |
|
| Consolidated Balance Sheets | ||
| Condensed Consolidated Interim Balance Sheet (P) | — |
|
| Consolidated Balance Sheets (P) | ||
| Condensed Consolidated Interim Statements of Operations (unaudited) | — |
|
| Consolidated Statements of Operations | ||
| Condensed Consolidated Interim Statements of Stockholders' Equity (deficiency) (unaudited) | — |
|
| Condensed Consolidated Interim Statements of Stockholders' Equity (unaudited) | — |
|
| Consolidated Statements of Stockholders' Equity | ||
| Consolidated Statements of Stockholders' Equity (deficit) | ||
| Condensed Consolidated Interim Statements of Cash Flows (unaudited) | — |
|
| Consolidated Statements of Cash Flows | ||
| Consolidated Statements of Stockholders' Equity (deficit) (P) | ||
| Notes | ||
| Accounts Payable and Accrued Expenses | ||
| Accounts Payable and Accrued Liabilities | ||
| Accounts Payable, Debt, and Accrued Expenses | — |
|
| Acquisition | — |
|
| Award Timing Disclosure | — |
|
| Clinical Trial Deposit | ||
| Clinical Trials Grant | ||
| Commitments and Contingencies | ||
| Convertible Promissory Notes | — |
|
| Cybersecurity Risk Management, Strategy, and Governance | — |
|
| Debt | — |
|
| Description of Business | — |
|
| Description of Business and Basis of Presentation | — |
|
| Fair Value Measurements | — |
|
| Financial Instruments | — |
|
| Financial Risk Management | — |
|
| Income Taxes | ||
| Insider Trading Arrangements | ||
| Insider Trading Policies and Procedures | — |
|
| Liquidity and Management's Plans | ||
| Merger With Kineta, Inc. | — |
|
| Merger With Kintara Therapeutics | — |
|
| Milestone Payment Liability | — |
|
| Nature of Operations, Corporate History, and Going Concern and Management Plans | ||
| Net Loss Per Share | ||
| Other Current Assets | ||
| Pay Vs Performance Disclosure | ||
| Property and Equipment, Net | ||
| Related Party Transactions | ||
| Significant Accounting Policies | ||
| Stock Option Plans | ||
| Stockholders' Equity | ||
| Subsequent Events | ||
| Summary of Significant Accounting Policies | ||
| Supplementary Statement of Cash Flows Information | ||